<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Sci Technol</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Sci Technol</journal-id><journal-id journal-id-type="pmc-domain-id">967</journal-id><journal-id journal-id-type="pmc-domain">jdst</journal-id><journal-id journal-id-type="publisher-id">DST</journal-id><journal-title-group><journal-title>Journal of Diabetes Science and Technology</journal-title></journal-title-group><issn pub-type="epub">1932-2968</issn><publisher><publisher-name>Diabetes Technology Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9445339</article-id><article-id pub-id-type="pmcid-ver">PMC9445339.1</article-id><article-id pub-id-type="pmcaid">9445339</article-id><article-id pub-id-type="pmcaiid">9445339</article-id><article-id pub-id-type="pmid">34032128</article-id><article-id pub-id-type="doi">10.1177/19322968211015268</article-id><article-id pub-id-type="publisher-id">10.1177_19322968211015268</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0169-6682</contrib-id><name name-style="western"><surname>Cobelli</surname><given-names initials="C">Claudio</given-names></name><degrees>PhD</degrees><xref rid="aff1-19322968211015268" ref-type="aff">1</xref><xref rid="corresp1-19322968211015268" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4908-0596</contrib-id><name name-style="western"><surname>Dalla Man</surname><given-names initials="C">Chiara</given-names></name><degrees>PhD</degrees><xref rid="aff2-19322968211015268" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff1-19322968211015268"><label>1</label>Department of Woman and Child&#8217;s Health University of Padova, Padova, Italy</aff><aff id="aff2-19322968211015268"><label>2</label>Department of Information Engineering, University of Padova, Padova, Italy</aff><author-notes><corresp id="corresp1-19322968211015268">Claudio Cobelli, PhD, Department of Woman and Child&#8217;s Health, University of Padova, Via N. Giustiniani, 3, Padova 35128, Italy. Email: <email>cobelli@dei.unipd.it</email></corresp><fn fn-type="COI-statement"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>5</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2022</year></pub-date><volume>16</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">416330</issue-id><fpage>1270</fpage><lpage>1298</lpage><pub-history><event event-type="pmc-release"><date><day>25</day><month>05</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>19</day><month>09</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-02 20:25:29.130"><day>02</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 Diabetes Technology Society</copyright-statement><copyright-year>2021</copyright-year><copyright-holder content-type="society">Diabetes Technology Society</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_19322968211015268.pdf"/><abstract><p>Several models have been proposed to describe the glucose system at whole-body, organ/tissue and cellular level, designed to measure non-accessible parameters (minimal models), to simulate system behavior and run in silico clinical trials (maximal models). Here, we will review the authors&#8217; work, by putting it into a concise historical background. We will discuss first the parametric portrait provided by the <italic toggle="yes">oral minimal models</italic>&#8212;building on the classical intravenous glucose tolerance test minimal models&#8212;to measure otherwise non-accessible key parameters like insulin sensitivity and beta-cell responsivity from a physiological oral test, the mixed meal or the oral glucose tolerance tests, and what can be gained by adding a tracer to the oral glucose dose. These models were used in various pathophysiological studies, which we will briefly review. A deeper understanding of insulin sensitivity can be gained by measuring insulin action in the skeletal muscle. This requires the use of isotopic tracers: both the classical multiple-tracer dilution and the positron emission tomography techniques are discussed, which quantitate the effect of insulin on the individual steps of glucose metabolism, that is, bidirectional transport plasma-interstitium, and phosphorylation. Finally, we will present a cellular model of insulin secretion that, using a multiscale modeling approach, highlights the relations between minimal model indices and subcellular secretory events. In terms of <italic toggle="yes">maximal models</italic>, we will move from a parametric to a flux portrait of the system by discussing the triple tracer meal protocol implemented with the tracer-to-tracee clamp technique. This allows to arrive at quasi-model independent measurement of glucose rate of appearance (Ra), endogenous glucose production (EGP), and glucose rate of disappearance (Rd). Both the fast absorbing simple carbs and the slow absorbing complex carbs are discussed. This rich data base has allowed us to build the UVA/Padova Type 1 diabetes and the Padova Type 2 diabetes large scale simulators. In particular, the UVA/Padova Type 1 simulator proved to be a very useful tool to safely and effectively test in silico closed-loop control algorithms for an artificial pancreas (AP). This was the first and unique simulator of the glucose system accepted by the U.S. Food and Drug Administration as a substitute to animal trials for in silico testing AP algorithms. Recent uses of the simulator have looked at glucose sensors for non-adjunctive use and new insulin molecules.</p></abstract><kwd-group><kwd>diabetes</kwd><kwd>insulin action</kwd><kwd>insulin secretion</kwd><kwd>stabilized tracers</kwd><kwd>multiscale modeling</kwd><kwd>in silico simulation</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-19322968211015268"><funding-source id="funding1-19322968211015268"><institution-wrap><institution>ministero dell&#8217;istruzione, dell&#8217;universita e della ricerca</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003407</institution-id></institution-wrap></funding-source><award-id rid="funding1-19322968211015268">Departments of Excellence, Law 232/2016</award-id></award-group><award-group id="award2-19322968211015268"><funding-source id="funding2-19322968211015268"><institution-wrap><institution>European Commission</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000780</institution-id></institution-wrap></funding-source><award-id rid="funding2-19322968211015268">HORIZON2020 - FET FORGETDIABETES, EU951933</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>